New agreement between National Comprehensive Cancer Network and Syapse will augment health information technology around cancer care
| PLYMOUTH MEETING, Pa., Nov. 1, 2018 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced a new agreement with Syapse, the leading precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precision oncology programs. The data contained in the NCCN Biomarkers Compendium® will strengthen Syapse’s decision support and workflow tools, increasing access to more personalized care.
“Treatment recommendations for people with cancer are expanding and improving rapidly, and that is particularly the case with precision medicine,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “The experts who sit on the various NCCN Guidelines Panels are at the forefront of advances in using genes and gene products for diagnosis, screening, monitoring, surveillance, and other aspects of cancer care. The latest updates from our guidelines are included in the NCCN Biomarkers Compendium, which will now support the point-of-care decision-making tools from Syapse.” The NCCN Biomarkers Compendium is part of NCCN’s Library of Compendia, which also includes databases for Drugs & Biologics (NCCN Compendium®), as well as the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™). The NCCN Compendium® is recognized by public and private insurers alike, including CMS and UnitedHealthcare, as an authoritative reference for oncology coverage policy. The recommendations contained in the Library of NCCN Compendia are extracted directly from the relevant NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and are updated on a continuous basis. “To bring precision medicine to more patients in more places, it is essential for organizations across the healthcare industry to work together,” said Ken Tarkoff, CEO of Syapse. “The NCCN Biomarkers Compendium is universally recognized as the expert resource for genetic testing in patients. We are eager to support our health system oncologists by integrating NCCN’s latest guidelines into the Syapse platform.” The NCCN-supported data will begin appearing on the Syapse platform in late 2018. Syapse is committed to updating that content weekly to keep pace with the NCCN Guidelines. “Harnessing technology to share the latest evidence- and expert consensus-based information on biomarkers allows clinicians to make well-informed decisions more efficiently,” said Dr. Carlson. “That means they’ll have more time for the patients who need them.” About the National Comprehensive Cancer Network Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCNnews and Facebook @National.Comprehensive.Cancer.Network. About Syapse Media Contacts: Courtney Lamie, Crosscut Strategies (Syapse)
SOURCE National Comprehensive Cancer Network |
View original content to download multimedia:
